India’s Revised Biosimilar Guidelines Ready In A Month
This article was originally published in PharmAsia News
A top Indian government official says revisions to the government’s regulatory guidelines for the development of biosimilars, which could herald the next wave of opportunity for the country's $15bn drug industry, should be ready in a month and will "address ethical questions."
You may also be interested in...
The first wave of biosimilars seemed ready to come to market in 2015, but only one product actually made it through FDA. The coming year might be the year when multiple biosimilars enter the US.
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.